Epigenetic modifications and emerging therapeutic targets in cardiovascular aging and diseases
The complex mechanisms underlying the development of cardiovascular diseases remain not fully elucidated. Epigenetics, which modulates gene expression without DNA sequence changes, is shedding light on these mechanisms and their heritable effects. This review focus on epigenetic regulation in cardio...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Pharmacological Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661824004912 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553849067765760 |
|---|---|
| author | Yurou Qiu Qing Xu Peichen Xie Chenshuang He Qiuchan Li Xin Yao Yang Mao Xiaoqian Wu Tiejun Zhang |
| author_facet | Yurou Qiu Qing Xu Peichen Xie Chenshuang He Qiuchan Li Xin Yao Yang Mao Xiaoqian Wu Tiejun Zhang |
| author_sort | Yurou Qiu |
| collection | DOAJ |
| description | The complex mechanisms underlying the development of cardiovascular diseases remain not fully elucidated. Epigenetics, which modulates gene expression without DNA sequence changes, is shedding light on these mechanisms and their heritable effects. This review focus on epigenetic regulation in cardiovascular aging and diseases, detailing specific epigenetic enzymes such as DNA methyltransferases (DNMTs), histone acetyltransferases (HATs), and histone deacetylases (HDACs), which serve as writers or erasers that modify the epigenetic landscape. We also discuss the readers of these modifications, such as the 5-methylcytosine binding domain proteins, and the erasers ten-eleven translocation (TET) proteins. The emerging role of RNA methylation, particularly N6-methyladenosine (m6A), in cardiovascular pathogenesis is also discussed. We summarize potential therapeutic targets, such as key enzymes and their inhibitors, including DNMT inhibitors like 5-azacytidine and decitabine, HDAC inhibitors like belinostat and givinotide, some of which have been approved by the FDA for various malignancies, suggesting their potential in treating cardiovascular diseases. Furthermore, we highlight the role of novel histone modifications and their associated enzymes, which are emerging as potential therapeutic targets in cardiovascular diseases. Thus, by incorporating the recent studies involving patients with cardiovascular aging and diseases, we aim to provide a more detailed and updated review that reflects the advancements in the field of epigenetic modification in cardiovascular diseases. |
| format | Article |
| id | doaj-art-d21c58c02c56419ca2ea4e445d682f55 |
| institution | Kabale University |
| issn | 1096-1186 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pharmacological Research |
| spelling | doaj-art-d21c58c02c56419ca2ea4e445d682f552025-01-09T06:13:03ZengElsevierPharmacological Research1096-11862025-01-01211107546Epigenetic modifications and emerging therapeutic targets in cardiovascular aging and diseasesYurou Qiu0Qing Xu1Peichen Xie2Chenshuang He3Qiuchan Li4Xin Yao5Yang Mao6Xiaoqian Wu7Tiejun Zhang8GMU-GIBH Joint School of Life Sciences, Department of Cardiology, Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, the Second Affiliated Hospital, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, State Key Laboratory of Respiratory Disease, The Sixth School of Clinical Medicine, the Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Guangdong Pharmaceutical University, Guangzhou, Guangdong, PR ChinaGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, PR ChinaGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, PR ChinaSchool of Bioscience and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, Guangdong, PR ChinaGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, PR ChinaGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, PR ChinaGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, PR ChinaGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, PR China; Corresponding authors.GMU-GIBH Joint School of Life Sciences, Department of Cardiology, Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, the Second Affiliated Hospital, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, State Key Laboratory of Respiratory Disease, The Sixth School of Clinical Medicine, the Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Guangzhou, Guangdong, PR China; Corresponding authors.The complex mechanisms underlying the development of cardiovascular diseases remain not fully elucidated. Epigenetics, which modulates gene expression without DNA sequence changes, is shedding light on these mechanisms and their heritable effects. This review focus on epigenetic regulation in cardiovascular aging and diseases, detailing specific epigenetic enzymes such as DNA methyltransferases (DNMTs), histone acetyltransferases (HATs), and histone deacetylases (HDACs), which serve as writers or erasers that modify the epigenetic landscape. We also discuss the readers of these modifications, such as the 5-methylcytosine binding domain proteins, and the erasers ten-eleven translocation (TET) proteins. The emerging role of RNA methylation, particularly N6-methyladenosine (m6A), in cardiovascular pathogenesis is also discussed. We summarize potential therapeutic targets, such as key enzymes and their inhibitors, including DNMT inhibitors like 5-azacytidine and decitabine, HDAC inhibitors like belinostat and givinotide, some of which have been approved by the FDA for various malignancies, suggesting their potential in treating cardiovascular diseases. Furthermore, we highlight the role of novel histone modifications and their associated enzymes, which are emerging as potential therapeutic targets in cardiovascular diseases. Thus, by incorporating the recent studies involving patients with cardiovascular aging and diseases, we aim to provide a more detailed and updated review that reflects the advancements in the field of epigenetic modification in cardiovascular diseases.http://www.sciencedirect.com/science/article/pii/S1043661824004912EpigeneticsEpigenetics-related regulatory mechanismsCardiovascular diseasesPotential targetsEpigenetic modification |
| spellingShingle | Yurou Qiu Qing Xu Peichen Xie Chenshuang He Qiuchan Li Xin Yao Yang Mao Xiaoqian Wu Tiejun Zhang Epigenetic modifications and emerging therapeutic targets in cardiovascular aging and diseases Pharmacological Research Epigenetics Epigenetics-related regulatory mechanisms Cardiovascular diseases Potential targets Epigenetic modification |
| title | Epigenetic modifications and emerging therapeutic targets in cardiovascular aging and diseases |
| title_full | Epigenetic modifications and emerging therapeutic targets in cardiovascular aging and diseases |
| title_fullStr | Epigenetic modifications and emerging therapeutic targets in cardiovascular aging and diseases |
| title_full_unstemmed | Epigenetic modifications and emerging therapeutic targets in cardiovascular aging and diseases |
| title_short | Epigenetic modifications and emerging therapeutic targets in cardiovascular aging and diseases |
| title_sort | epigenetic modifications and emerging therapeutic targets in cardiovascular aging and diseases |
| topic | Epigenetics Epigenetics-related regulatory mechanisms Cardiovascular diseases Potential targets Epigenetic modification |
| url | http://www.sciencedirect.com/science/article/pii/S1043661824004912 |
| work_keys_str_mv | AT yurouqiu epigeneticmodificationsandemergingtherapeutictargetsincardiovascularaginganddiseases AT qingxu epigeneticmodificationsandemergingtherapeutictargetsincardiovascularaginganddiseases AT peichenxie epigeneticmodificationsandemergingtherapeutictargetsincardiovascularaginganddiseases AT chenshuanghe epigeneticmodificationsandemergingtherapeutictargetsincardiovascularaginganddiseases AT qiuchanli epigeneticmodificationsandemergingtherapeutictargetsincardiovascularaginganddiseases AT xinyao epigeneticmodificationsandemergingtherapeutictargetsincardiovascularaginganddiseases AT yangmao epigeneticmodificationsandemergingtherapeutictargetsincardiovascularaginganddiseases AT xiaoqianwu epigeneticmodificationsandemergingtherapeutictargetsincardiovascularaginganddiseases AT tiejunzhang epigeneticmodificationsandemergingtherapeutictargetsincardiovascularaginganddiseases |